Диссертация (1140658), страница 19
Текст из файла (страница 19)
– Т.156. – №. 5. – 1565-1572 p.129. Netchiporouk E., Litvinov I.V., Moreau L., Gilbert M., Sasseville D.,Duvic M. Deregulation in STAT signaling is important for cutaneous T-celllymphoma (CTCL) pathogenesis and cancer progression //Cell Cycle. –2014. – Т. 13. – №. 21. – 3331-3335 p.130. Nickoloff B. J. Light-microscopic assessment of 100 patients withpatch/plaque-stagemycosisfungoides//TheAmericanJournalofdermatopathology. – 1988. – Т.
10. – №. 6. – 469-477 p131. Niederhuber J.E., Armitage J.O., Doroshow J.H., Kastan M.B., TepperJ.E. Abeloff’s clinical oncology. Elsevier, 2014. - 2060–2075 p.132. Nikolaou V., Siakantaris M. P., Vassilakopoulos T. P., Papadavid E.,Stratigos A., Economidi A., Antoniou C. PUVA plus interferon α2b in thetreatment of advanced or refractory to PUVA early stage mycosis fungoides:a case series //Journal of the European Academy of Dermatology andVenereology. – 2011. – Т. 25. – №.
3. – 354-357 p.133. Nishikomori R., Usui T, Wu CY, Morinobu A, O'Shea JJ, Strober W.Activated STAT4 has an essential role in Th1 differentiation and143proliferation that is independent of its role in the maintenance of IL-12Rβ2chain expression and signaling //The Journal of Immunology. – 2002. – Т.169. – №. 8. – 4388-4398 p.134. Oguz O., Engin B., Aydemir E. H. The influence of psoralen+ultraviolet A treatment on the duration of remission and prognosis inmycosis fungoides //Journal of the European Academy of Dermatology andVenereology. – 2003.
– Т. 17. – №. 4. – 483-485 p.135. Olivier M., Goldgar D. E., Sodha N., Ohgaki H., Kleihues P., HainautP., Eeles R. A. Li-Fraumeni and related syndromes: correlation betweentumor type, family structure, and TP53 genotype //Cancer research. – 2003.– Т.
63. – №. 20. – 6643-6650 p.136. Olsen E.A., Whittaker S., Kim Y. H., Duvic M., Prince H. M., LessinS. R., Bernengo M. G. Clinical end points and response criteria in mycosisfungoides and Sézary syndrome: a consensus statement of the InternationalSociety for Cutaneous Lymphomas, the United States Cutaneous LymphomaConsortium, and the Cutaneous Lymphoma Task Force of the EuropeanOrganisation for Research and Treatment of Cancer //Journal of ClinicalOncology. – 2011. – Т. 29. – №. 18.
– 2598-2607 p.137. Querfeld C., Rosen S. T., Kuzel T. M., Kirby K. A., Roenigk H. H.,Prinz B. M., Guitart J. Long-term follow-up of patients with early-stagecutaneous T-cell lymphoma who achieved complete remission with psoralenplus UV-A monotherapy //Archives of dermatology. – 2005. – Т. 141. – №.3.
– 305-311 p.138. Ralfkiaer U., Hagedorn P.H., Bangsgaard N., Lovendorf M.B., AhlerC.B., Svensson L. Diagnostic microRNA profiling in cutaneous T-celllymphoma (CTCL) //Blood. – 2011. – Т. 118. – №. 22. – 5891-5900 p.139. Rodd A. L., Ververis K., Karagiannis T. C.
Current and emergingtherapeutics for cutaneous T-Cell lymphoma: histone deacetylase inhibitors//Lymphoma. – 2012. – Т. 2012. – 1-10 p.144140. Rodríguez-Gil Y., Palencia S.I., Lopez-Rios F., Ortiz P.L., RodriguezPeralto J.L.. Mycosis fungoides after solid-organ transplantation: report of 2new cases //The American Journal of Dermatopathology. – 2008.
– Т. 30. –№. 2. – 150-155 p.141. Roupe G., Sandström M. H., Kjellström C. PUVA in early mycosisfungoides may give long-term remission and delay extracutaneous spread//Acta dermato-venereologica. – 1996. – Т. 76. – №. 6. – 475-478 p.142. Rupoli S., Goteri G., Pulini S., Filosa A., Tassetti A., Offidani M.,Cataldi I. Long‐term experience with low‐dose interferon‐α and PUVA inthe management of early mycosis fungoides //European journal ofhaematology. – 2005. – Т.
75. – №. 2. – 136-145 p.143. Samman P.D. The natural history of parapsoriasis en plaques (chronicsuperficial dermatitis) and prereticulotic poikiloderma //British Journal ofDermatology. – 1972. – Т. 87. – №. 5. – 405-411 p.144. Sanchez J. L., Ackerman A. B. The patch stage of mycosis fungoides.Criteriaforhistologicdiagnosis//TheAmericanJournalofdermatopathology.
– 1979. – Т. 1. – №. 1. – 5-26 p.145. Santucci M, Biggeri A, Feller AC, Massi D, Burg G. Efficacy ofhistologic criteria for diagnosing early mycosis fungoides: an EORTCcutaneous lymphoma study group investigation //The American journal ofsurgical pathology.
– 2000. – Т. 24. – №. 1. – 40 p.146. Sekulović L. K., Cikota, B., Popović, M., Stojadinovic, O., Tarabar,O., Bašanović, J., Magić, Z. TCRγ gene rearrangement analysis in skinsamples and peripheral blood of mycosis fungoides patients //ActaDermatovenerologica Alpina, Pannonica et Adriatica. – 2007. – Т. 16. – №.4. – 149-155 p.147. Smoller B. R. Immunoperoxidase techniques in the evaluation ofcutaneous lymphocytic infiltrates //Seminars in cutaneous medicine andsurgery.
– 1996. – Т. 15. – №. 4. – 300-307 p.145148. Smoller B. R., Bishop K., Glusac E., Kim Y.H., Hendrickson M.Reassessment of histologic parameters in the diagnosis of mycosis fungoides//The American journal of surgical pathology. – 1995. – Т. 19. – №. 12. –1423-1430 p.149. Sommer V. H., Clemmensen O.J., Nielsen O., Wasik M., Lovato P.,Brender C.
In vivo activation of STAT3 in cutaneous T-cell lymphoma.Evidence for an antiapoptotic function of STAT3 //Leukemia. – 2004. – Т.18. – №. 7. – 1288-1295 p.150. Southern E. M. Detection of specific sequences among DNAfragments separated by gel electrophoresis //Journal of molecular biology. –1975. – Т. 98. – №. 3. – 503-517 p.151. Spaccarelli N., Rook A. H. The use of interferons in the treatment ofcutaneous T-cell lymphoma //Dermatologic clinics. – 2015. – Т. 33. – №. 4.– 731-745 p.152.
Swerdlow S. H., Campo E., Pileri S.A. The 2016 revision of theWorld Health Organization classification of lymphoid neoplasms //Blood. –2016. – Т. 127. – №. 20. – 2375-2390 p.153. Talpur R., Bassett R., Duvic M. Prevalence and treatment ofStaphylococcus aureus colonization in patients with mycosis fungoides andSézary syndrome //British Journal of Dermatology. – 2008. – Т. 159. – №. 1.– 105-112 p.154. Tili E, Michaille JJ, Wernicke D, Alder H, Costinean S, Volinia S,Croce CM.
Mutator activity induced by microRNA-155 (miR-155) linksinflammation and cancer //Proceedings of the National Academy ofSciences. – 2011. – Т. 108. – №. 12. – 4908-4913 p.155. Toonstra J., Wildschut A., Boer J., Smeenk G., Willemze R., van derPutte S. C., van Vloten W. A. Jessner's lymphocytic infiltration of the skin: aclinical study of 100 patients //Archives of dermatology.
– 1989. – Т. 125. –№. 11. – 1525-1530 p.146156. Trautinger F., Eder J., Assaf C., Bagot M., Cozzio A., Dummer R.,Pimpinelli N. European Organisation for Research and Treatment of Cancerconsensus recommendations for the treatment of mycosis fungoides/Sézarysyndrome–Update 2017 //European journal of cancer. – 2017. – Т. 77. – 5774 p.157. Villeneuve P. J., Agnew D. A., Miller A. B., Corey P. N. NonHodgkin's lymphoma among electric utility workers in Ontario: theevaluation of alternate indices of exposure to 60 Hz electric and magneticfields //Occupational and environmental medicine. – 2000.
– Т. 57. – №. 4. –249-257 p.158. Warin A. P., Briffa D. V., Harrington C. I., Bleehen S. S.Photochemotherapy in mycosis fungoides--a study of fifty-six patients[proceedings] //The British journal of dermatology. – 1979. – Т. 101. – 4953 p.159. Wolverton S. E.
Comprehensive dermatologic drug therapy. –Elsevier Health Sciences, 2012.160. Willemze R., JLM Meijer C. Classification of cutaneous T‐celllymphoma: from Alibert to WHO‐EORTC //Journal of cutaneous pathology.– 2006. – Т. 33. – 18-26 p.161. Willerslev-Olsen A., Litvinov I.V., Fredholm S.M., Petersen D.L.,Sibbesen D. L., Gniadecki N. A. IL-15 and IL-17F are differentiallyregulated and expressed in mycosis fungoides (MF) // Cell cycle. – 2014. –Т. 13.
– №. 8. – С. 1306-1312.162. Wong O., Fu H. Exposure to benzene and non-Hodgkin lymphoma, anepidemiologic overview and an ongoing case-control study in Shanghai//Chemico-biological interactions. – 2005. – Т. 153. – 33-41 p.163. Wu J., Nihal M, Siddiqui J, Vonderheid EC. Low FAS/CD95expression by CTCL correlates with reduced sensitivity to apoptosis that canbe restored by FAS upregulation //Journal of Investigative Dermatology. –2009. – Т.
129. – №. 5. – 1165-1173 p.147164. Wysocka M., Benoit B.M., Newton S. Enhancement of the hostimmuneresponsesincutaneousT-celllymphomabyCpGoligodeoxynucleotides and IL-15 //Blood. – 2004. – Т. 104. – №. 13. –4142-4149 p.165. Yang H., Xu C., Tang Y., Wan, C., Liu W., Wang L.
The significanceof multiplex PCR/heteroduplex analysis‐based TCR‐γ gene rearrangementcombined with laser‐capture microdissection in the diagnosis of earlymycosis fungoides //Journal of cutaneous pathology. – 2012. – Т. 39. – №.3. – 337-346 p.166. Zackheim H. S., McCalmont T.
H. Mycosis fungoides: the greatimitator //Journal of the American Academy of Dermatology. – 2002. – Т.47. – №. 6. – 914-918 p.167. Zhang Y., Wang Y., Yu R, Huang Y., Su M., Xiao C., Martinka M.,Dutz J.P., Zhang X., Zheng Z., Zhou Y. Molecular markers of early-stagemycosis fungoides //Journal of Investigative Dermatology.
– 2012. – Т. 132.– №. 6. – 1698-1706 p.148ПРИЛОЖЕНИЕ А. Стадирование грибовидного микоза/синдрома Сезарисогласно рекомендациям ISCL-EORTC [Olsen]СтадияT(кожа)N(лимфатические узлы)IAT1: ограниченные пятна,папулы, и/или бляшки,покрывающие <10%кожного покрова:Т1а – только пятнаТ1b – бляшки ± пятнаТ2: пятна, папулы, и/илибляшки, покрывающие>10% кожного покрова:Т2а – только пятнаТ2b - бляшки ± пятнаN0: Нет увеличенияпериферическихлимфатических узлов, ихбиопсия не требуетсяIBIIAT1-2IIBIIIAIIIBIVA1IVA2Т3: Один или более узлов(≥1 см в диаметре)Т4: Сливающаяся эритема,покрывающая ≥80%поверхности телаT4Т1-4Т1-4N0: Нет увеличенияпериферическихлимфатических узлов, ихбиопсия не требуетсяN1: Периферическиелимфатические узлыувеличены; гистопатологияDutch grade 1 или NCI LN0-2LN1a – клон-негативныLN1b – клон-позитивныилиN2: Периферическиелимфатические узлыувеличены; гистопатологияDutch grade 2 или NCI LN3LN2a – клон-негативныLN2b – клон-позитивныM0M0N0-2M0N0-2M0N0-2N0-2N3: Периферическиелимфатические узлыувеличены; гистопатологияDutch grade 3-4 или NCILN4, клон-позитивны илинегативныM0M0M0IVBТ1-4M(внутренниеорганы)M0: НетвовлечениявнутреннихоргановN0-3M1: Вовлечениевнутреннихорганов (суточнениеморгана иморфологическимподтверждением)149ПРИЛОЖЕНИЕ Б.
Диагностический алгоритм ранних стадий грибовидногомикозаПримечание. ХДД – хронический доброкачественный дерматоз, ГМ – грибовидный микоз.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
